Repligen Corp (NASDAQ:RGEN)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.

Results 1 - 20 of 61 : 1 2 3 4 Next »

Recs

0
Member Avatar pchop123 (78.31) Submitted: 4/16/2014 2:44:05 PM : Outperform Start Price: $15.29 RGEN Score: +3.21

heading back upwards in stk price

Recs

0
Member Avatar TerryFool (21.60) Submitted: 3/28/2014 9:07:27 AM : Outperform Start Price: $13.61 RGEN Score: +14.24

RGEN BUY 12 TP 16 1YR EPS 45%

Recs

4
Member Avatar grankh (87.50) Submitted: 2/6/2014 5:54:49 PM : Outperform Start Price: $14.68 RGEN Score: +1.69

This is a real-life holding of mine in my investment club.

Sales have grown at an annual compound growth rate of 20% since 2008. EPS has grown at an annual compound growth rate of 32% since 2008. (Though there have been lots of fluctuations over this time span.) The profit margin and earned-on-equity has been increasing recently. The company has no debt. The current P/E, (at 20.2), is inline with recent averages, (at 19.5), so reasonably priced. The PEG ratio is an attractive 0.63. The company does not pay a dividend.

I think the stock could return 22% annually over the next 5 years, if it continues growing as it has. This would more than double my money in 5 years time. Here's hoping the stock performs as hoped.

Recs

0
Member Avatar dbajack2 (26.66) Submitted: 1/15/2014 1:17:00 PM : Outperform Start Price: $12.21 RGEN Score: +28.77

Market attracting new people again for awhile... hype attracts, heath care is making money.

Recs

0
Member Avatar drbry64 (< 20) Submitted: 12/27/2013 3:14:38 PM : Outperform Start Price: $12.68 RGEN Score: +23.51

bioresearch up

Recs

0
Member Avatar gr8twhtebuffalo (43.15) Submitted: 12/13/2013 6:39:22 PM : Outperform Start Price: $12.74 RGEN Score: +20.18

Biotech boom.

Recs

1
Member Avatar ZipMeck (30.36) Submitted: 11/18/2013 2:22:27 PM : Outperform Start Price: $13.08 RGEN Score: +17.73

This company have products that a couple of major drug companies need for their cancer/ medical researches. Expansion is already on order for production. This is a 10-bagger.

Recs

1
Member Avatar kickbishopbrenna (35.72) Submitted: 11/13/2013 9:17:39 AM : Outperform Start Price: $12.61 RGEN Score: +19.77

I just read "1 stock to buyin Nov" and agree, this "one trick pony" is about to build a new stable.

Recs

0
Member Avatar olipapa01 (< 20) Submitted: 11/10/2013 4:12:32 AM : Outperform Start Price: $12.02 RGEN Score: +26.55

2014 will be the best year of repligen yet, i wait to see how much is inside of this microcap stocks

Recs

0
Member Avatar Stregachess (< 20) Submitted: 10/3/2013 12:06:37 AM : Outperform Start Price: $11.25 RGEN Score: +30.37

Biotech Rocks that's all I'm saying..

Recs

2
Member Avatar zzlangerhans (99.73) Submitted: 6/17/2013 3:25:34 PM : Outperform Start Price: $7.67 RGEN Score: +93.47

I missed the bump in Repligen's share price in the spring because I set an outperform threshold of 6 that never quite clicked. The stock has been pulling back over the last month but I still like the growing bioprocessing revenues, courtesy of the excellent acquisition of Novozymes Biopharma Sweden AB in 2011. Repligen still has to outgrow a well-deserved reputation for futility but if they can successfully transition from drug development into products and services there's still a lot of potential for share price appreciation.

Recs

0
Member Avatar TerryHoodSr (49.09) Submitted: 5/27/2013 3:30:28 PM : Outperform Start Price: $7.87 RGEN Score: +86.25

3 YR rev growth 34%

Recs

0
Member Avatar Karate460 (64.53) Submitted: 4/10/2013 1:12:12 PM : Outperform Start Price: $9.14 RGEN Score: +55.83

Getting contracts with strong manufactures is the key to growth and they are getting that.

Recs

1
Member Avatar Skyshadow664 (< 20) Submitted: 6/14/2012 2:25:44 PM : Underperform Start Price: $4.09 RGEN Score: -246.99

These medical corporations tend to have spurts of large growth with long periods of notable decline. Just as Genetic Technologies as been fluctuating over the past year (a range from ~$2.50 - ~$10.00), this company follows a very similar trend. It will have spurts when it has a break through but overall it will underplay the market.

Recs

0
Member Avatar ghc4 (< 20) Submitted: 4/27/2012 12:15:41 PM : Outperform Start Price: $4.50 RGEN Score: +219.22

There is money in drugs

Recs

0
Member Avatar Biotoday (44.93) Submitted: 3/29/2011 3:40:50 PM : Outperform Start Price: $3.71 RGEN Score: +285.59

Oversold on bad news.

Recs

1
Member Avatar Groovatorium (35.12) Submitted: 9/11/2010 9:44:21 PM : Outperform Start Price: $3.45 RGEN Score: +293.57

Get ready, this one's due. The phase 3 trial of their pancreatic secretin analogue has Fast Track and Orphan status and will be vital in diagnosing pancreatic disease with MRI. I'm thinking this technology will give Repligen a big boost in early 2011. MRI is the imaging modality of the future as it becomes more accessible and affordable, and this product will prove very useful as that occurs.

Pancreatic imaging, fools!

Recs

0
Member Avatar GreatStocks3728 (< 20) Submitted: 3/18/2010 7:47:23 AM : Outperform Start Price: $3.64 RGEN Score: +276.01

Good growth and earnings.

Recs

0
Member Avatar iddqkfyou (< 20) Submitted: 1/26/2010 11:33:05 AM : Outperform Start Price: $3.46 RGEN Score: +287.07

Insider purchase at higher price

Results 1 - 20 of 61 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement